Medium materiality6/10
Zymeworks (ZYME) Reiterated at Market Outperform by Citizens on FDA Approval for Zani
Why it may matterVerify against the original reporting
Upside implied by PT above price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Deutsche Bank reiterates Market Outperform on ZYME; PT $32; price $27.47.
- Deutsche Bank reiterates ZYME Market Outperform; PT $32; price $27.47.
Key facts
- 01
Target: $32
- 02
Posted price: $27.47
- 03
Analyst firm: Deutsche Bank
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.